Our pipeline:
multiple modalities and novel targets

We are committed to delivering life-changing RNA medicines so that patients and families can realize a brighter future.

Our pipeline is differentiated and diversified, spanning multiple modalities including RNA editing, splicing and silencing, as well as several disease areas.

*Through GSK collaboration, Wave can advance up to three collaboration programs (the first of which is INHBE) and GSK can advance up to eight collaboration programs.

AATD: Alpha-1 antitrypsin deficiency; DMD: Duchenne muscular dystrophy; HD: Huntington's disease Editing for correction Editing for upregulation

RNA Editing

WVE-006

SERPINA1 (AATD)

Multiple undisclosed
Correction

Multiple undisclosed
Upregulation

Splicing

WVE-N531

Exon 53 (DMD)

Other exons (DMD)

SILENCING: ANTISENSE

WVE-003

mHTT (HD)

SILENCING: siRNA

INHBE* (metabolic disorders, including obesity)

*Through GSK collaboration, Wave can advance up to three collaboration programs (the first of which is INHBE) and GSK can advance up to eight collaboration programs.

AATD: Alpha-1 antitrypsin deficiency; DMD: Duchenne muscular dystrophy; HD: Huntington's disease Editing for correction Editing for upregulation

Cancel Continue